JP2017176174A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017176174A5 JP2017176174A5 JP2017057024A JP2017057024A JP2017176174A5 JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5 JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017057024 A JP2017057024 A JP 2017057024A JP 2017176174 A5 JP2017176174 A5 JP 2017176174A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- region
- same amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 17
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10320408P | 2008-10-06 | 2008-10-06 | |
| US61/103,204 | 2008-10-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014226709A Division JP6230983B2 (ja) | 2008-10-06 | 2014-11-07 | Ｍｕｃ１＊抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017176174A JP2017176174A (ja) | 2017-10-05 |
| JP2017176174A5 true JP2017176174A5 (cg-RX-API-DMAC7.html) | 2017-11-16 |
| JP6392923B2 JP6392923B2 (ja) | 2018-09-19 |
Family
ID=42101177
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531128A Pending JP2012504961A (ja) | 2008-10-06 | 2009-10-06 | Ｍｕｃ１＊抗体 |
| JP2014226709A Active JP6230983B2 (ja) | 2008-10-06 | 2014-11-07 | Ｍｕｃ１＊抗体 |
| JP2017057024A Active JP6392923B2 (ja) | 2008-10-06 | 2017-03-23 | Ｍｕｃ１＊抗体 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011531128A Pending JP2012504961A (ja) | 2008-10-06 | 2009-10-06 | Ｍｕｃ１＊抗体 |
| JP2014226709A Active JP6230983B2 (ja) | 2008-10-06 | 2014-11-07 | Ｍｕｃ１＊抗体 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20170204191A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4083072A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2012504961A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101455447B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102239182B (cg-RX-API-DMAC7.html) |
| CR (1) | CR20110238A (cg-RX-API-DMAC7.html) |
| IL (1) | IL212175B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010042562A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4083072A1 (en) | 2008-10-06 | 2022-11-02 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| US11898160B2 (en) * | 2008-10-09 | 2024-02-13 | Minerva Biotechnologies Corporation | Method for maintaining pluripotency in cells |
| US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
| EP3228629A1 (en) * | 2010-06-16 | 2017-10-11 | Minerva Biotechnologies Corporation | Reprogramming cancer cells |
| EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| EP2686418A4 (en) * | 2011-03-17 | 2015-04-22 | Minerva Biotechnologies Corp | METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS |
| CN102716472A (zh) * | 2011-03-31 | 2012-10-10 | 李光辉 | 一种肿瘤疫苗及其合成方法 |
| AU2013289913A1 (en) * | 2012-07-13 | 2015-03-05 | Minerva Biotechnologies Corporation | Method for inducing cells to less mature state |
| CN104717980A (zh) * | 2012-08-14 | 2015-06-17 | 米纳瓦生物技术公司 | 干细胞增强疗法 |
| US9770011B2 (en) | 2012-09-29 | 2017-09-26 | The Trustees Of The University Of Pennsylvania | Veterinary composition and methods for non-surgical neutering and castration |
| CN103848890B (zh) * | 2012-11-30 | 2015-09-09 | 北京市结核病胸部肿瘤研究所 | Muc1自身抗体识别的抗原多肽 |
| CA2898239A1 (en) * | 2013-01-23 | 2014-07-31 | Syddansk Universitet | Mfap4 binding antibodies blocking the interaction between mfap4 and integrin receptors |
| JP6908381B2 (ja) | 2014-01-29 | 2021-07-28 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｕｃ１−ｃ／細胞外ドメイン（ｍｕｃ１−ｃ／ｅｃｄ）に対する抗体 |
| CN103880956B (zh) * | 2014-03-10 | 2015-12-30 | 中国人民解放军第四军医大学 | 抗muc1单克隆抗体及其轻链和重链可变区 |
| EP4050103A1 (en) | 2014-04-07 | 2022-08-31 | Minerva Biotechnologies Corporation | Anti-nme antibody |
| US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
| AU2015316522B2 (en) * | 2014-09-16 | 2021-01-21 | Symphogen A/S | Anti-met antibodies and compositions |
| KR102390359B1 (ko) * | 2014-09-29 | 2022-04-22 | 삼성전자주식회사 | 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체 |
| US20180148514A1 (en) | 2014-10-02 | 2018-05-31 | City Of Hope | Multivalent meditopes, meditope-binding antibodies and uses thereof |
| WO2016057683A2 (en) * | 2014-10-07 | 2016-04-14 | Ann And Robert H. Lurie Children's Hospital Of Chicago | Novel anti-nodal antibodies and methods of using same |
| AU2016219350A1 (en) | 2015-02-10 | 2017-08-24 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies |
| MX2018006973A (es) * | 2015-12-09 | 2019-05-16 | Corvus Pharmaceuticals Inc | Anticuerpos anti-cd73 humanizados. |
| EP4245775A3 (en) * | 2016-04-29 | 2023-11-15 | Benhealth Biopharmaceutic (Shenzhen) Co. Ltd. | Multi-specific binding conjugate, related pharmaceutical compositions and use |
| US20190343953A1 (en) * | 2017-01-27 | 2019-11-14 | Glycotope Gmbh | Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor |
| CN110650976B (zh) * | 2017-04-13 | 2024-04-19 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| CN109971713B (zh) * | 2017-12-28 | 2023-06-20 | 上海细胞治疗研究院 | 稳定表达PD-1抗体的Muc1特异性CAR-T细胞及其用途 |
| BR112020016005A2 (pt) * | 2018-02-07 | 2020-12-15 | Regeneron Pharmaceuticals, Inc. | Método de administração de uma proteína terapêutica ao sistema nervoso central, proteína terapêutica multidomínio, polinucleotídeo, vetor de terapia gênica, e, uso de um nucleotídeo que codifica a proteína terapêutica multidomínio |
| US20200405832A1 (en) * | 2018-03-09 | 2020-12-31 | Minerva Biotechnologies Corporation | Method for anti-muc1* car t cell stimulation |
| CN120484122A (zh) * | 2019-01-11 | 2025-08-15 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| WO2020163325A1 (en) | 2019-02-04 | 2020-08-13 | Minerva Biotechnologies Corporation | Anti-nme antibody and method of treating cancer or cancer metastasis |
| EP4161970A4 (en) | 2020-06-08 | 2024-07-10 | Minerva Biotechnologies Corporation | ANTI-NME ANTIBODIES AND METHODS FOR TREATING CANCER OR CANCER METASTASES |
| IL299332A (en) | 2020-06-26 | 2023-02-01 | Minerva Biotechnologies Corp | Anti-nme antibody and method of treating cancer or cancer metastasis |
| IL299903A (en) * | 2020-07-16 | 2023-03-01 | Dana Farber Cancer Inst Inc | Antibodies against the MUC1-C/EXTRACELLULAR domain (MUC1-C/ECD) |
| EP4188432A4 (en) * | 2020-07-31 | 2024-08-21 | R.P. Scherer Technologies, LLC | ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF |
| CN119317447A (zh) | 2022-04-12 | 2025-01-14 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| EP4646444A1 (en) * | 2023-01-04 | 2025-11-12 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Anti-muc1 antibodies and uses thereof |
| US20240261406A1 (en) | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
| WO2025080693A1 (en) | 2023-10-11 | 2025-04-17 | Minerva Biotechnologies Corporation | Anti-muc1* antibody drug complexes and uses thereof |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| GB9412230D0 (en) | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
| US5874540A (en) | 1994-10-05 | 1999-02-23 | Immunomedics, Inc. | CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| US20020136725A1 (en) * | 1996-01-17 | 2002-09-26 | Smithkline Beecham Corporation | Antithrombotic agents |
| TWI242563B (en) * | 1998-04-30 | 2005-11-01 | Tanox Inc | Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor |
| DE69941031D1 (de) | 1998-11-12 | 2009-08-06 | Novolytics Inc | Zusammensetzungen und verfahren zur erzeugung von gefässeokklusion |
| US20020064528A1 (en) * | 2000-01-28 | 2002-05-30 | Zhenping Zhu | Antibodies specific to KDR and uses thereof |
| US20020052311A1 (en) * | 1999-09-03 | 2002-05-02 | Beka Solomon | Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders |
| US20020146750A1 (en) * | 2000-03-30 | 2002-10-10 | Hoogenboom Hendricus R.J.M. | Mucin-1 specific binding members and methods of use thereof |
| DE60130891T2 (de) | 2000-06-29 | 2008-07-17 | Anthera Pharmaceuticals Inc., San Mateo | Heilmittel für krebs |
| DE60140461D1 (de) * | 2000-09-11 | 2009-12-24 | Genzyme Corp | Muc1 extrazelluläre domäne und zusammensetzungen für krebsbehandlung, und davon abgeleitete verfahren |
| DK2322929T3 (en) * | 2000-11-27 | 2016-07-25 | Minerva Biotechnologies Corp | Diagnostics, pharmaceutical screening and treatment of cancer |
| JP2005508839A (ja) * | 2001-03-29 | 2005-04-07 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | ペプチドおよびｍｕｃ１タンパク質に対する抗体 |
| US7630836B2 (en) | 2001-05-30 | 2009-12-08 | The Kitasato Institute | Polynucleotides |
| JP2005507876A (ja) | 2001-09-05 | 2005-03-24 | ミナーバ バイオテクノロジーズ コーポレイション | 癌を治療する組成物および方法 |
| WO2003074566A2 (en) | 2002-03-01 | 2003-09-12 | Immunomedics, Inc. | Rs7 antibodies |
| JP2006504630A (ja) | 2002-04-22 | 2006-02-09 | ダイアックス コーポレイション | ムチンポリペプチドに特異的な抗体 |
| KR101143035B1 (ko) * | 2002-06-14 | 2012-05-08 | 이뮤노메딕스, 인코오포레이티드 | 단클론 항체 ｈＰＡＭ4 |
| EP2363410B1 (en) | 2002-11-27 | 2017-10-11 | Minerva Biotechnologies Corporation | Isoforms of MUC1 |
| US7101978B2 (en) | 2003-01-08 | 2006-09-05 | Applied Molecular Evolution | TNF-α binding molecules |
| US20060173171A1 (en) | 2003-08-26 | 2006-08-03 | Bamdad Cynthia C | Techniques and compositions for diagnosis and treatment of cancer (muci) |
| EP3653641A1 (en) | 2004-02-19 | 2020-05-20 | Genentech, Inc. | Cdr-repaired antibodies |
| JP4937127B2 (ja) * | 2004-10-04 | 2012-05-23 | ジェネンテック， インコーポレイテッド | 肝細胞成長因子活性化物質のモジュレータ |
| EP1875244B1 (en) * | 2005-03-30 | 2019-01-23 | Minerva Biotechnologies Corporation | Proliferation of muc1 expressing cells |
| CN101652469B (zh) | 2006-12-06 | 2014-04-16 | 米纳瓦生物技术公司 | 用于鉴定和操作细胞的方法 |
| WO2008073817A2 (en) * | 2006-12-08 | 2008-06-19 | Dana-Farber Cancer Institute, Inc. | Muc1 and galectin-3 |
| EP4083072A1 (en) | 2008-10-06 | 2022-11-02 | Minerva Biotechnologies Corporation | Muc1* antibodies |
| CN104717980A (zh) * | 2012-08-14 | 2015-06-17 | 米纳瓦生物技术公司 | 干细胞增强疗法 |
| AU2016219350A1 (en) * | 2015-02-10 | 2017-08-24 | Minerva Biotechnologies Corporation | Humanized anti-MUC1* antibodies |
-
2009
- 2009-10-06 EP EP22161931.5A patent/EP4083072A1/en active Pending
- 2009-10-06 EP EP09819788A patent/EP2337801A4/en not_active Withdrawn
- 2009-10-06 CN CN200980148911.6A patent/CN102239182B/zh not_active Expired - Fee Related
- 2009-10-06 US US12/574,693 patent/US20170204191A1/en not_active Abandoned
- 2009-10-06 EP EP16190400.8A patent/EP3130607B1/en active Active
- 2009-10-06 US US15/501,768 patent/US10421819B2/en active Active
- 2009-10-06 JP JP2011531128A patent/JP2012504961A/ja active Pending
- 2009-10-06 KR KR1020117010349A patent/KR101455447B1/ko active Active
- 2009-10-06 WO PCT/US2009/059754 patent/WO2010042562A2/en not_active Ceased
-
2011
- 2011-04-06 IL IL212175A patent/IL212175B/en active IP Right Grant
- 2011-05-06 CR CR20110238A patent/CR20110238A/es unknown
-
2014
- 2014-11-07 JP JP2014226709A patent/JP6230983B2/ja active Active
-
2017
- 2017-03-23 JP JP2017057024A patent/JP6392923B2/ja active Active
-
2019
- 2019-08-13 US US16/539,247 patent/US11560435B2/en active Active
-
2022
- 2022-12-06 US US18/062,377 patent/US20230295340A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017176174A5 (cg-RX-API-DMAC7.html) | ||
| JP2018504907A5 (cg-RX-API-DMAC7.html) | ||
| AU2018256487A1 (en) | Antibodies that bind to TL1A and their uses | |
| JP2019524645A5 (cg-RX-API-DMAC7.html) | ||
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| JP2014205674A5 (cg-RX-API-DMAC7.html) | ||
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2016185981A5 (cg-RX-API-DMAC7.html) | ||
| WO2016207304A3 (en) | Monoclonal anti-il-1racp antibodies | |
| JP2019528240A5 (cg-RX-API-DMAC7.html) | ||
| CN113316591A (zh) | Cd73抗体及其制备方法和应用 | |
| NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
| EA201991577A1 (ru) | Новые антитела против рецептора трансферрина человека, способные преодолевать гематоэнцефалический барьер | |
| NZ630610A (en) | Tau peptides, anti-tau antibodies, and methods of use thereof | |
| CN110291109A (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| JP2013539454A5 (cg-RX-API-DMAC7.html) | ||
| AR105267A1 (es) | Anticuerpos de unión a tau | |
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| PE20190737A1 (es) | Anticuerpos anti-cd27 | |
| JP2018537399A5 (cg-RX-API-DMAC7.html) | ||
| WO2019066435A3 (ko) | Bcma에 높은 친화도를 가지는 항-bcma 항체 및 이를 포함하는 암 치료용 약학적 조성물 |